KFU. Card publication. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

MUSASHI 2 (MSI2) EXPRESSION AS AN INDEPENDENT PROGNOSTIC BIOMARKER IN NON-SMALL CELL LUNG CANCER (NSCLC)

Form of presentation

Articles in international journals and collections

Year of publication

2021

��

��

Authors, employees of KFU

Abramova Zinaida Ivanovna, author

Serebriyskiy Ilya Genrikhovich, author

Tikhomirova Mariya Vladimirovna, author

Yugay Veronika Nikolaevna, author

Other authors

Ratner Ekaterina Yurevna, author

Authors, postgraduates KFU

Mazitova Aleksandra Maratovna, postgraduate kfu

Bibliographic description in the original language

Topchu I. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)/ Iu.Topchu, N. Karnaukhov, A. Mazitova, […], Z. Abramova, I. Serebriiskii, Y. Boumber, A. Deneka //Journal of Thoracic Disease. - 2021. - Vol.13, Is.3. - P.1370-1379. (Q2, IF2.895)

Annotation

Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.

Keywords

musashi-2 (MSI2), non-small cell lung cancer (NSCLC), RNA binding proteins, overall survival (OS), prediction biomarkers

The name of the journal

JOURNAL OF THORACIC DISEASE

URL

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103498654&doi=10.21037%2fjtd-20-2787&partnerID=40&md5=abc542b021fb7e500bc59da3213b8aa2

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=252913&p_lang=2

Resource files

File name	Size (MB)	Format
F_Musashi_2__MSI2__biomarker.pdf	1,43	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Abramova Zinaida Ivanovna	ru_RU
dc.contributor.author	Serebriyskiy Ilya Genrikhovich	ru_RU
dc.contributor.author	Tikhomirova Mariya Vladimirovna	ru_RU
dc.contributor.author	Yugay Veronika Nikolaevna	ru_RU
dc.contributor.author	Ratner Ekaterina Yurevna	ru_RU
dc.contributor.author	Mazitova Aleksandra Maratovna	ru_RU
dc.date.accessioned	2021-01-01T00:00:00Z	ru_RU
dc.date.available	2021-01-01T00:00:00Z	ru_RU
dc.date.issued	2021	ru_RU
dc.identifier.citation	Topchu I. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)/ Iu.Topchu, N. Karnaukhov, A. Mazitova, […], Z. Abramova, I. Serebriiskii, Y. Boumber, A. Deneka //Journal of Thoracic Disease. - 2021. - Vol.13, Is.3. - P.1370-1379. (Q2, IF2.895)	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=252913&p_lang=2	ru_RU
dc.description.abstract	JOURNAL OF THORACIC DISEASE	ru_RU
dc.description.abstract	Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	musashi-2 (MSI2)	ru_RU
dc.subject	non-small cell lung cancer (NSCLC)	ru_RU
dc.subject	RNA binding proteins	ru_RU
dc.subject	overall survival (OS)	ru_RU
dc.subject	prediction biomarkers	ru_RU
dc.title	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)	ru_RU
dc.type	Articles in international journals and collections	ru_RU